Case–control study of second‐line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 12, 2015-12 ,pp. : 1194-1197

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of diabetes‐associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 573-580

John Wiley & Sons Inc

Access to resources Recommend Favorite

Oral antidiabetic agents in type 2 diabetes

By Levetan Claresa  

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 945-952

Informa Healthcare

Access to resources Recommend Favorite

Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study

By Goldstein Barry J.   Weissman Peter N.   Wooddell Margaret J.   Waterhouse Brian R.   Cobitz Alexander R.  

Current Medical Research and Opinion, Vol. 22, Iss. 9, 2006-09 ,pp. : 1715-1723

Informa Healthcare

Access to resources Recommend Favorite

Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus

By Mitchell Beth D.   Eby Elizabeth L.   Lage Maureen J.  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1587-1597

Informa Healthcare

Access to resources Recommend Favorite